These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17325349)

  • 1. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
    Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
    Blake N; Lee S; Redchenko I; Thomas W; Steven N; Leese A; Steigerwald-Mullen P; Kurilla MG; Frappier L; Rickinson A
    Immunity; 1997 Dec; 7(6):791-802. PubMed ID: 9430224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
    J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
    Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
    J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
    Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
    Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
    Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
    J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
    Jones K; Nourse JP; Morrison L; Nguyen-Van D; Moss DJ; Burrows SR; Gandhi MK
    Blood; 2010 Sep; 116(13):2245-52. PubMed ID: 20562330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
    Midgley RS; Bell AI; Yao QY; Croom-Carter D; Hislop AD; Whitney BM; Chan AT; Johnson PJ; Rickinson AB
    J Virol; 2003 Nov; 77(21):11507-16. PubMed ID: 14557636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.